Search Results for 'Evotec, Janssen in Depression Agreement'

Search For:
Refine by Dates:
From: To:
Refine By Content:

  • Evotec, Janssen in Depression Agreement

    December 17, 2012
    Janssen to develop NMDA antagonist treatments

  • Forest Gains Lexapro Approval in Adolescents

    March 23, 2009
    Forest Laboratories received approval from the FDA for its sNDA for Lexapro for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adolescents, ages 12 to 17.

  • Risperdal Consta sNDA Submitted

    April 14, 2008
    Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a Supplemental New Drug Application (sNDA) for Risperdal Consta  to the FDA seeking approval for adjunctive maintenance treatment to delay the occurr…

  • Wyeth's Pristiq Approved for MDD

    March 3, 2008
    Wyeth Pharmaceuticals received approval from the FDA for Pristiq, a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD). Wyeth expects to begin shipping the d…

  • AZ Submits sNDAs for Seroquel XR

    January 2, 2008
    AstraZeneca submitted two sNDAs to the FDA for once-daily Seroquel XR Extended-Release Tablets in the following indications: treatment of manic episodes associated with bipolar disorder and treatment of depressive episodes associated with bipolar dis…

  • Memory's Drug Fails IIa Trial in Bipolar Disorder

    March 5, 2007
    Memory Pharmaceuticals' Phase IIa study of MEM 1003 in acute mania in bipolar disorder, based on primary and secondary outcome measures in the trial, did not prove effective. The multi-center, double-blind, randomized, placebo-controlled study e…